- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 May 2025 | 5 May 2025 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31 2025 Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2025 (As Per BSE Announcement Dated on :13.05.2025) | ||
| Board Meeting | 17 Mar 2025 | 17 Mar 2025 |
| Outcome of Board meeting held on Monday, March 17, 2025 | ||
| Board Meeting | 4 Feb 2025 | 29 Jan 2025 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 Unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2024 (As per BSE Announcement Dated on 04/02/2025) | ||
| Board Meeting | 9 Dec 2024 | 4 Dec 2024 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/12/2024 ,inter alia, to consider and approve issuance of equity shares of the Company on a preferential basis and Postal ballot notice. Acquisition of the 100% stake in Core Diagnostics Private Limited, India, (Core Diagnostics) from its existing shareholder, Core Diagnostics (Mauritius) Private Limited for a total purchase consideration of INR 246.83 crores to be discharged partly by cash and partly by way of preferential issue and allotment of equity shares of the Company Preferential Issue (As per BSE Announcement Dated on 09/12/2024) | ||
| Board Meeting | 8 Nov 2024 | 30 Oct 2024 |
| Quarterly Results Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement Dated on 08/11/2024) | ||
| Board Meeting | 10 Aug 2024 | 5 Aug 2024 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024 Financial Results for the quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 10/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.